About: Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential
Creator	Coughlin, Melissa Prabhakar, Bellur
Source	Medline; PMC
abstract	The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) led to a rapid response not only to contain the outbreak but also to identify possible therapeutic interventions, including the generation of human monoclonal antibodies (hmAbs). Human mAbs may be used therapeutically without the drawbacks of chimeric or animal Abs. Several different methods have been used to generate SARS-CoV specific neutralizing hmAbs including the immunization of transgenic mice, cloning of small chain variable regions from naïve and convalescent patients, and the immortalization of convalescent B cells. Irrespective of the techniques used, the majority of hmAbs specifically reacted with the receptor binding domain (RBD) of the spike (S) protein and likely prevented receptor binding. However, several hmAbs that can bind to epitopes either within the RBD, located N terminal of the RBD or in the S2 domain and neutralize the virus with or without inhibiting receptor binding have been identified. Therapeutic utility of hmAbs has been further elucidated through the identification of potential combinations of hmAbs that could neutralize viral variants including escape mutants selected using hmAbs. These results suggest that a cocktail of hmAbs which can bind to unique epitopes and have different mechanisms of action might be of clinical utility against SARS-CoV infection, and indicate that a similar approach may be applied to treat other viral infections.
has issue date	2011-09-08(xsd:dateTime)
bibo:doi	10.1002/rmv.706
bibo:pmid	21905149
has license	bronze-oa
sha1sum (hex)	3ae33811b40f90704493fb1e4417e0b976ff75d8
schema:url	https://doi.org/10.1002/rmv.706
resource representing a document's title	Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential
has PubMed Central identifier	PMC3256278
has PubMed identifier	21905149
schema:publication	Reviews in Medical Virology
resource representing a document's body	covid:3ae33811b40f90704493fb1e4417e0b976ff75d8#body_text
is schema:about of	named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'RBD' named entity 'reacted' named entity 'protein' named entity 'human monoclonal antibodies' named entity 'outbreak' named entity 'RBD' named entity 'neutralize' named entity 'variable' named entity 'ACTION' named entity 'CONVALESCENT' named entity 'UNIQUE' named entity 'BUT' named entity 'IDENTIFICATION' named entity 'EMERGENCE' named entity 'CHIMERIC' named entity 'VARIANTS' named entity 'POSSIBLE' named entity 'VIRUS' named entity 'EITHER' named entity 'PATIENTS' named entity 'RECEPTOR BINDING' named entity 'SELECTED' named entity 'EPITOPES' named entity 'COCKTAIL' named entity 'INHIBITING' named entity 'GENERATION' named entity 'THERAPEUTIC' named entity 'SMALL' named entity 'SPECIFIC' named entity 'SUGGEST' named entity 'TECHNIQUES' named entity 'IMMUNIZATION' named entity 'THERAPEUTIC' named entity 'MONOCLONAL ANTIBODIES' named entity 'HUMAN' named entity 'MECHANISMS' named entity 'COMBINATIONS' named entity 'B CELLS' named entity 'IDENTIFIED' covid:arg/3ae33811b40f90704493fb1e4417e0b976ff75d8 named entity 'BIND' named entity 'RESULTS' named entity 'VARIABLE' named entity 'POTENTIAL' named entity 'GENERATE' named entity 'MECHANISM OF ACTION' named entity 'APPROACH' named entity 'HAVE' named entity 'MAJORITY' named entity 'CHAIN' named entity 'RESPONSE' named entity 'TO CONTAIN' named entity 'ABS' named entity 'ESCAPE' named entity 'VIRAL INFECTIONS' named entity 'DOMAIN' named entity 'LIKELY' named entity 'CLONING' named entity 'USED' named entity 'INCLUDING' named entity 'TERMINAL' named entity 'USING' named entity 'THESE' named entity 'TARGET' named entity 'TREAT' named entity '28S' named entity 'SARS-COV' named entity 'SIMILAR' named entity 'DIFFERENT' named entity 'RBD' named entity 'APPLIED' named entity 'METHODS' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'MUTANTS' named entity 'PROTEIN ' named entity 'ANIMAL' named entity 'MONOCLONAL ANTIBODIES' named entity 'HUMAN' named entity 'UTILITY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software